[Addendum to Commission A13-09 (vandetanib)]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018002960
German
Original Title:
Addendum zum Auftrag A13-09 (Vandetanib [erneute Bewertung gemaeß § 35a Absatz 5b SGB V])
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a13-26.html
Year Published:
2013
URL for published report:
https://www.iqwig.de/download/A13-26_Addendum-zum-Auftrag-A13-09_Vandetanib.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Thyroid Neoplasms
- Antineoplastic Agents
- Piperidines
- Quinazolines
Keywords
- Vandetanib
- Thyroid Neoplasms
- Benefit Assessment
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.